Bio-Rad Laboratories (BIO) Releases Earnings Results, Misses Expectations By $-0.18 EPS

Bio-Rad Laboratories (BIO) reported quarterly earnings results on Thursday, May-5-2016. The company reported $0.42 earnings per share for the quarter, missing the analyst consensus estimate by $-0.18. Analysts had a consensus of $0.60. The company posted revenue of $471.20 million in the period, compared to analysts expectations of $463.92 million. The company’s revenue was down -.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.61 EPS.

Bio-Rad Laboratories closed down -0.89 points or -0.62% at $142.33 with 1,02,996 shares getting traded on Wednesday. Post opening the session at $143.05, the shares hit an intraday low of $141.71 and an intraday high of $144.29 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Mar 14, 2016, Christine A Tsingos (EVP and CFO) sold 6,630 shares at $137.81 per share price. According to the SEC, on Dec 15, 2015, Shawn Marie Soderberg (EVP, General Counsel, Sec) sold 1,900 shares at $135.50 per share price. On Nov 20, 2015, Giovanni Magni (EVP, Chief Strategy Officer) sold 6,000 shares at $140.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Bio-Rad Laboratories Inc. (Bio-Rad) manufactures and supplies products and systems used for the life science research healthcare analytical chemistry and other markets. The Company offers products to separate complex chemical and biological materials and to identify analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Company’s Life Science segment develops manufactures and markets a range of over 5000 reagents apparatus and laboratory instruments. The Company’s Clinical Diagnostics segment designs manufactures sells and supports test systems informatics systems test kits and quality controls that serve clinical laboratories in the global diagnostics market. Bio-Rad’s product brands include Droplet Digital and BioPlex. As of December 31 2014 the Company had direct distribution channels in over 35 countries outside the United States through subsidiaries.

Bio-Rad Laboratories

Leave a Reply

Bio-Rad Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bio-Rad Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.